GO
Loading...

Regeneron Pharmaceuticals Inc

More

  • Cramer: Six buyable themes in second half Tuesday, 1 Jul 2014 | 6:08 PM ET
    Jim Cramer on Mad Money.

    Cramer says the price action in Tuesday’s market is sending an important message about what to buy in the days ahead.

  • Midday movers: Alstom, CarMax, Sprint & More Friday, 20 Jun 2014 | 11:34 AM ET

    Some of Friday's midday movers:

  • Beleaguered biotechs about to rally: Charts Wednesday, 4 Jun 2014 | 6:26 PM ET

    For the past several months biotech stocks have fallen out of favor on Wall Street. That may be about to change.

  • Valeant's New York- listed shares dropped 1 percent by midday to $128.66, paring earlier losses, while Allergan stock lost 4.1 percent to $158.29. Valeant on Wednesday offered to pay $58.30 per Allergan share in cash, about $10 higher than its previous offer of $48.30.

  • Valeant increases bid for Botox-maker Allergan Wednesday, 28 May 2014 | 12:09 PM ET
    Botox by Allergan

    Canadian drugmaker Valeant Pharmaceuticals International raised the cash component of its offer for Botox-maker Allergan by $10 per share.

  • UPDATE 2-Valeant injects cash into bid for Botox maker Wednesday, 28 May 2014 | 9:06 AM ET

    Valeant on Wednesday offered to pay $58.30 per Allergan share in cash, about $10 higher than its previous offer of $48.30. The new offer values Allergan at $166.16 per share as of Tuesday's closing price, and is about 8.6 percent higher than the previous bid of $153 as on April 22 when Valeant first made its offer.

  • Valeant on Wednesday offered to pay $58.30 per Allergan share in cash, about $10 higher than its previous offer of $48.30. The new offer values Allergan at $166.16 per share as of Tuesday's closing price, and is about 8.6 percent higher than the previous bid of $153 as on April 22 when Valeant first made its offer.

  • TIMELINE-Early signs of pushback over U.S. drug prices Wednesday, 28 May 2014 | 1:00 AM ET

    May 28- Gilead Sciences' $84,000 treatment for hepatitis C, Sovaldi, has broken the sales record for drug launches and caused a backlash among insurers concerned by the cost.

  • Top 10 highest paid CEOs Tuesday, 27 May 2014 | 7:42 AM ET
    Les Moonves, president and chief executive officer of CBS Corp.

    Here are the 10 highest-paid CEOs of 2013, as calculated by The Associated Press and Equilar, an executive pay research firm.

  • May 19- Ophthotech Corp said it could potentially receive over $1 billion in payments as part of a licensing deal for its experimental eye drug with Novartis AG. Ophthotech's shares rose as much as 29 percent in trading after the bell.

  • ANALYSIS-Pfizer-AstraZeneca deal not quite dead yet Monday, 19 May 2014 | 6:36 PM ET

    NEW YORK, May 19- Pfizer Inc may have called its $118 billion bid for AstraZeneca Plc a "final" offer, and its British rival sees no prospect of a deal being revived. Morningstar analyst Damien Conover in Chicago said the odds of an AstraZeneca purchase had fallen well below the 50 percent mark.

  • Midday movers: NFLX, PCLN, BIIB & more Thursday, 15 May 2014 | 12:23 PM ET
    NYSE exchange floor

    Take a look at some of Thursday's midday movers:

  • Midday movers: Aaron's, Eli Lilly, Gogo & More Monday, 12 May 2014 | 12:30 PM ET
    NYSE EuroNext flag hangs outside the NYSE.

    Some of Monday's midday movers:

  • Even biotechs blame the weather Thursday, 8 May 2014 | 12:49 PM ET

    It's been a gloomy week for biotech earnings, and many have blamed their poor results on, of all things, the weather.

  • May 8- U.S. sales of Regeneron Pharmaceuticals Inc's eye drug Eylea missed market estimates due to a drop in distributor inventory and a severe U.S. winter that prevented patients from visiting clinics to receive the treatment. Sales of the drug outside the United States increased more than three-fold, to $218 million.

  • Early movers: AZN, TM, TSLA, RIG & more Thursday, 8 May 2014 | 7:38 AM ET
    Traders work the floor of the New York Stock Exchange on the evening of January 23, 2014 in New York City.

    Some of the names on the move ahead of the open.

  • Regeneron's adjusted quarterly profit beats estimates Thursday, 8 May 2014 | 6:43 AM ET

    May 8- Regeneron Pharmaceuticals Inc posted a better-than-expected adjusted profit for the first quarter, helped by strong sales of its eye drug, Eylea. The biotechnology company's net income fell to $65.4 million, or 58 cents per share, in the quarter ended March 31 from $98.9 million, or 90 cents per share, a year earlier.

  • Cramer’s game plan: Disney, Whole Foods & others Friday, 2 May 2014 | 6:09 PM ET

    Cramer says there will be plenty of opportunities to make money in the week ahead. But you'll have to stay alert and move fast.

  • Where Apple's stock-split leads, others may follow Thursday, 24 Apr 2014 | 3:52 PM ET

    Apple becomes the fourth member of the S&P 500 to announce a split in 2014.

  • Midday movers: Post Holdings, Tyson Foods, Yelp & More Wednesday, 16 Apr 2014 | 12:30 PM ET

    Some of Wednesday's midday movers: